WHEN YOU CAN TRACK THE KEY EVENTS
                   THAT IMPACT A PRODUCT OR COMPANY'S VALUATION,

    THAT'S INTELLIGENCE YOU CAN ACT ON.

                                                                           Learn more

WHEN YOU CAN EASILY DETERMINE
THAT A NEW THERAPY CATEGORY
IS A MARKET OPPORTUNITY,







THAT'S INTELLIGENCE YOU CAN ACT ON.

    

Learn more

                                                                                                                       

data driven solutions

customised to your specific business challenges

      

evaluate custom services

                                                                 LEARN MORE

          

EUROPEAN DRUG FORECASTS TO 2022

THE FIRST STANDARDISED CONSENSUS BASED 

DRUG FORECASTS FOR EUROPE

                                                           LEARN MORE

Select ImageSelect ImageSelect ImageSelect Image
Page BannerPage BannerPage BannerPage Banner

Service Temporarily Unavailable

Our team are currently in the process of updating the security we have installed on the site. Please be patient as we hope to have our service running again very soon.

Market intelligence leader in consensus forecasts and analysis of the life science industry

Biotechnology | Pharmaceutical | Medical Device | Diagnostic

Explore Evaluate Premier Services:

March 05, 2013

Leader in consensus forecast analysis of the biotech and pharma sector providing trusted insight into global performance to 2022. March 05, 2013

New standard in integrated analysis and consensus forecasts to 2022 of the medical device and diagnostic industry. March 05, 2013

Unique clinical trial intelligence integrated and standardized to efficiently analyze the global clinical trial landscape.
March 05, 2013
Explore EvaluatePharma Explore EvaluateMedTech Explore EvaluateClinical Trials

Award-winning daily commentary and analysis with fresh perspectives and insight into current and future industry trends.

March 05, 2013
Explore EPVantage

February 24, 2016

Latest from Evaluate

PRESS RELEASE: Fast pace of drug and device approvals in 2017 signals wider sector health for biopharma but medtech companies struggle

More Reports

Find value faster with Evaluate

  • Consensus forecasts to 2022
  • High quality, transparent data   
  • Standardised, dynamic platform   
  • Evaluation tools and custom exports
  • Friendly, expert support

Request a demo

What our customers are saying

When I think of the future, I think of EvaluatePharma 

Senior Director,
Global pharmaceutical company

Read more customer testimonials